|
Optovent AB is a development company with focus on platform
technologies for drug delivery. The primary application is within
cancer therapy and based on the RHCC proprietary technology.
RHCC provides a platform technology for improved cancer therapy.
The first application is with the potent, but toxic, drug cisplatin.
By use of RHCC as a drug deliverer, efficacy of cisplatin can be improved
and side-effects reduced, thus improving the therapeutic index.
The RHCC technology is in the pre-clinical phase.
|
|